Liver cancer is one of the three deadliest cancers worldwide, and metabolic dysfunction-related cases have become ...
Initiation of trial marks first-in-human milestone for Neomorph’s novel molecular glue degrader platformSAN DIEGO, Feb. 03, ...
The trial is being conducted in collaboration with the U.S. Department of Veterans Affairs (VA) and is fully funded through ...
New study reveals a central role of selenoprotein GPX3 in attenuating acute kidney injury Renal ischemia–reperfusion injury ...
In a human organoid-based mechanistic investigation, researchers revealed how an immunosuppressive drug, antithymocyte ...
Prof. Terence Lee, Associate Head and Professor of the PolyU Department of Applied Biology and Chemical Technology, and his ...
Hippocampi- targeted AAV-delivered BDNF gene therapy improves cognitive impairments in Alzheimer’s disease Alzheimer’s ...
Researchers show that loss of the SPRTN enzyme lets DNA–protein crosslinks accumulate, leak DNA into the cytoplasm, activate ...
This is the first trial combining Allarity's stenoparib with another anti-cancer agent Stenoparib's favorable safety profile supports potential for use in combination regimens Trial is fully funded by ...
Cells shrink a major internal structure as they age. New research shows this downsizing is deliberate—and linked to longer ...
Researchers identify beta catenin protein degradation as a therapeutic vulnerability in B cell acute lymphoblastic leukaemia, supporting the repurposing of glycogen synthase kinase 3 beta inhibitors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results